Lead Sponsor

AstraZeneca

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

•Signed written informed consent
•Female postmenopausal patient (or patient post-ovariectomy) and age ≥18 years Postmenopause ist defined as
•* Age ≥ 60 years and natural menopause with menses \> 1year ago or
•* FSH and E2 levels in the postmenopausal range or
•* Patients who had bilateral ovariectomy (NCCN V.I. 2009)
•Histologically confirmed ER+ locally advanced or metastatic breast cancer

•Prior treatment with tamoxifen
•Suitable to undergo endocrine treatment for ER+ ABC with SERD / sAI
•Patient is able to read and understand German
•Known hypersensitivity to Faslodex or Exemestane or any compounds of the drugs
•Prior treatment with Faslodex 500 mg or Faslodex 250 mg\*
•* for patients who receive treatment with Faslodex 500 mg within this observational study. Patients who are included in the exemestane arm may have received prior Faslodex treatment.
•Prior treatment with Exemestane for patients who receive treatment with Exemestane within this observational study
•Acutely life threatening disease
•Treatment with Faslodex 250 mg/month (previously approved dose)
•Prior palliative chemotherapy

Related studies

NCT06347068 · Breast Cancer, Relapse, and more

NCT06500481 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more

NCT07655934 · Breast Cancer

NCT07288359 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, and more

NCT06400563 · Breast Cancer

A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer